epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Evaluation of pituitary mass

OVERVIEW

  • Summary
  • Urgent Considerations
  • Etiology

DIAGNOSIS

  • Differential Diagnosis
  • Diagnostic Approach

IMAGES

  • Library

REFERENCES

  • Citations
  • Credits

Summary

AAFont SizeShareMore Information
The pituitary gland lies in the pituitary fossa (sella turcica), which is situated in the middle cranial fossa at the base of the brain. It is linked functionally to the hypothalamus by the pituitary stalk. The hypothalamus lies in a superior position to the pituitary gland, and the link between the two organs is critical for normal pituitary gland function.
The anterior pituitary secretes growth hormone, thyrotropin or thyroid-stimulating hormone, corticotropin or adrenocorticotropic hormone, follicle-stimulating hormone, luteinizing hormone, and prolactin. The posterior lobe secretes arginine vasopressin (also called antidiuretic hormone) and oxytocin.
Pituitary masses may be classified based on their underlying etiology: for example, pituitary adenoma, pituitary hyperplasia, nonadenomatous tumors, and vascular, inflammatory, or infective lesions.
Most pituitary masses are caused by a pituitary adenoma; these are benign tumors arising from the anterior pituitary gland. Pituitary adenomas are classified as functional (hormone secreting) or nonfunctional, and can be further categorized by cell type or size, for example, microadenomas (<10 mm) or macroadenomas (>10 mm).​[1]​[2] [3]
Pituitary masses may present with a clinical syndrome resulting from hypersecretion of ≥1 anterior pituitary hormones (e.g., Cushing disease, acromegaly). Alternatively, they may present more insidiously with mass effect or with tumor expansion leading to compression of surrounding structures, including normal pituitary tissue, resulting in hypopituitarism. Functional pituitary tumors can produce a complex picture of combined hormonal excess and/or deficiencies.[4]
Analyses using autopsy and radiologic data suggest primary adenoma prevalence rates of 14.4% and 22.5%, respectively (yielding an overall estimated prevalence rate of 16.7%).[5] Almost all of these are clinically silent microadenomas. The prevalence increases with age, and detection is more likely using high-resolution MRI sequences.[6]
content by BMJ Group
Last updated

Library

  • Plain computed tomography scan showing a small pituitary mass encroaching on the right cavernous sin

    Plain computed tomography scan showing a small pituitary mass encroaching on the right cavernous sinus

  • (A) Coronal T1 weighted magnetic resonance imaging (MRI) scan showing a pituitary mass with expansio

    (A) Coronal T1 weighted magnetic resonance imaging (MRI) scan showing a pituitary mass with expansion of the pituitary fossa. (B) Coronal T1 weighted MRI scan showing a pituitary mass extending into the cavernous sinus, particularly on the right. (C) Sagittal T1 weighted MRI scan of the pituitary tumor

  • Coronal (A) and sagittal (B) post-contrast magnetic resonance image T1 weighted sections showing a l

    Coronal (A) and sagittal (B) post-contrast magnetic resonance image T1 weighted sections showing a large intrasellar tumor with suprasellar component. Suprasellar solid component shows a lobulated margin with peripheral non-enhancing cystic areas (margins shown by arrows), which are mildly hyperintense compared with cerebrospinal fluid in basal cisterns

Citations

    Key Articles

    • Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023 Apr 25;329(16):1386-98.[Abstract]

    • Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:894-904.[Abstract][Full Text]

    • American College of Radiology. ACR appropriateness criteria. Neuroendocrine Imaging. 2018 [internet publication].[Full Text]

    Referenced Articles

    • 1. Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023 Apr 25;329(16):1386-98.[Abstract]

    • 2. Pal A, Leaver L, Wass J. Pituitary adenomas. BMJ. 2019 Jun 6;365:l2091.[Abstract]

    • 3. Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022 Mar;33(1):6-26.[Abstract]

    • 4. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer. 2001 Dec;8(4):287-305.[Abstract][Full Text]

    • 5. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004 Aug 1;101(3):613-9.[Abstract][Full Text]

    • 6. Morris Z, Whiteley WN, Longstreth WT Jr, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339:b3016.[Abstract][Full Text]

    • 7. Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021 Dec;50(4):104080.[Abstract][Full Text]

    • 8. Daly AF, Beckers A. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. 2020 Sep;49(3):347-55.[Abstract]

    • 9. Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;7:281-93.[Abstract][Full Text]

    • 10. Giuffrida G, Crisafulli S, Ferraù F, et al. Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022 Jun;45(6):1235-46.[Abstract]

    • 11. Crisafulli S, Luxi N, Sultana J, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021 Jul 1;185(2):251-63.[Abstract]

    • 12. Mercado M, Melgar V, Salame L, et al. Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects. [in spa]. Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):384-95.[Abstract]

    • 13. Shukla P, Bulsara KR, Luthra P. Pituitary hyperplasia in severe primary hypothyroidism: a case report and review of the literature. Case Rep Endocrinol. 2019;2019:2012546.[Abstract][Full Text]

    • 14. ​Cancer Research UK. Carniopharyngioma. Feb 2023 [internet publication].​[Full Text]

    • 15. Kucharczyk W, Truwit CL. Diseases of the sella turcica and parasellar region. In: Hodler J, Kubik-Huch RA, von Schulthess GK, eds. Diseases of the brain, head and neck, spine 2020-2023: diagnostic imaging [Internet]. Cham (CH): Springer; 2020. Chapter 1.​[Abstract][Full Text]

    • 16. Keles A, Olsen HT, Nisbet AF, et al. Primary midbrain germinomas: report of a rare case with an updated review of the literature. Clin Neurol Neurosurg. 2023 Apr;227:107643.[Abstract]

    • 17. Abucham J, Dias ML. Pituitary and other sellar region metastases. Curr Opin Endocrinol Metab Res​. 2018 Aug;1:36-41.​

    • 18. Schubiger O, Haller D. Metastases to the pituitary-hypothalamic axis: an MR study of 7 symptomatic patients. Neuroradiology. 1992;34:131-134.[Abstract]

    • 19. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997 Feb 15;79(4):804-12.[Abstract][Full Text]

    • 20. Beauchesne P, Trouillas J, Barral F, et al. Gonadotropic pituitary carcinoma: case report. Neurosurgery. 1995 Oct;37(4):810-5; discussion 815-6.[Abstract]

    • 21. Kaltsas GA, Nomikos P, Kontogeorgos G, et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005 May;90(5):3089-99.[Abstract][Full Text]

    • 22. Heaney AP. Clinical review: Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3649-3660.[Abstract]

    • 23. Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in Eendocrinology: hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018 Jun 7;179(3):R151-63.[Abstract]

    • 24. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014 Nov;99(11):4078-85.[Abstract][Full Text]

    • 25. Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015 Feb 15;21(4):749-55.[Abstract][Full Text]

    • 26. Torino F, Barnabei A, Paragliola RM, et al. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013 Dec;169(6):R153-64.[Abstract][Full Text]

    • 27. Mallereau CH, Todeschi J, Ganau M, et al. Pituitary abscess: a challenging preoperative diagnosis-a multicenter study. Medicina (Kaunas). 2023 Mar 14;59(3):565.[Abstract][Full Text]

    • 28. Heshmati HM, Fatourechi V, Dagam SA, et al. Hypopituitarism caused by intrasellar aneurysms. Mayo Clin Proc. 2001 Aug;76(8):789-93.[Abstract]

    • 29. Goyal P, Utz M, Gupta N, et al. Clinical and imaging features of pituitary apoplexy and role of imaging in differentiation of clinical mimics. Quant Imaging Med Surg. 2018 Mar;8(2):219-31.[Abstract][Full Text]

    • 30. Biagetti B, Sarria-Estrada S, Cordero Asanza E, et al. Risk factors, radiological and clinical outcomes in subclinical and clinical pituitary apoplexy. J Clin Med. 2022 Dec 8;11(24):7288.[Abstract][Full Text]

    • 31. Trifanescu R, Ansorge O, Wass JA, et al. Rathke's cleft cysts. Clin Endocrinol (Oxf). 2012 Feb;76(2):151-60.[Abstract][Full Text]

    • 32. Ucciferro P, Anastasopoulou C. Empty sella. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 [Abstract][Full Text]

    • 33. Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011 Apr;96(4):905-12.[Abstract][Full Text]

    • 34. Baldeweg SE, Vanderpump M, Drake W, et al. Society for Endocrinology endocrine emergency guidance: emergency management of pituitary apoplexy in adult patients. Endocr Connect. 2016 Sep;5(5):G12-G15.[Abstract][Full Text]

    • 35. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:894-904.[Abstract][Full Text]

    • 36. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101290.[Abstract][Full Text]

    • 37. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.[Abstract][Full Text]

    • 38. Gadelha MR, Kasuki L, Lim DST, et al. Systemic Complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019 Feb 1;40(1):268-332.[Abstract][Full Text]

    • 39. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Oct 30;99(11):3933-51.[Abstract][Full Text]

    • 40. Beck-Peccoz P, Persani L, Mannavola D, et al. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):597-606.[Abstract]

    • 41. Cappabianca P, Cirillo S, Alfieri A, et al. Pituitary macroadenoma and diaphragma sellae meningioma: differential diagnosis on MRI. Neuroradiology. 1999;41:22-26.[Abstract]

    • 42. Pinzer T, Krishnan KG, Schackert G. The diaphragma sellae meningioma: a rare differential diagnosis of non-functioning pituitary adenoma. Zentralbl Neurochir. 2004;65:195-197.[Abstract]

    • 43. Scott ES, Long GV, Guminski A, et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018 Feb;178(2):173-180.[Abstract][Full Text]

    • 44. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014 Apr;21(2):371-81.[Abstract][Full Text]

    • 45. Piloni M, Gagliardi F, Bailo M, et al. Craniopharyngioma in pediatrics and adults. Adv Exp Med Biol. 2023;1405:299-329.[Abstract]

    • 46. Zada G, Ditty B, McNatt SA, et al. Surgical treatment of rathke cleft cysts in children. Neurosurgery. 2009 Jun;64(6):1132-7; author reply 1037-8.[Abstract]

    • 47. Vroonen L, Daly AF, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019;109(1):20-7.[Abstract][Full Text]

    • 48. Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011;96:1633-1641.[Abstract]

    • 49. Chin BM, Orlandi RR, Wiggins RH 3rd. Evaluation of the sellar and parasellar regions. Magn Reson Imaging Clin N Am. 2012;20:515-543.[Abstract]

    • 50. American College of Radiology. ACR appropriateness criteria. Neuroendocrine Imaging. 2018 [internet publication].[Full Text]

    • 51. Shrivastava RK, Arginteanu MS, King WA, et al. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002;97:299-306.[Abstract]

    • 52. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273-288.[Abstract][Full Text]

    • 53. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40.[Abstract][Full Text]

    • 54. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-75.[Abstract][Full Text]

    • 55. Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 Nov;101(11):3888-921.[Abstract][Full Text]

    • 56. Jho DH, Biller BM, Agarwalla PK, et al. Pituitary apoplexy: large surgical series with grading system. World Neurosurg. 2014;82:781-790.[Abstract]

Have feedback?
Tell us about your experience
Scroll to Top
epocrates logo

Sign in to access our clinical decision support tools

Sign inCreate Account
Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information